Kelun-Biotech’s SKB264 Approved for Phase II Study in EGFR-Mutant NSCLC
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the National Medical Products...
Combination therapy
Adagene’s ADG126 Shows Promise in Combination with Anti-PD-1 Therapy
China-based biotech Adagene Inc. (NASDAQ: ADAG), which also operates out of San Diego, California, has...
Dizal’s Sunvozertinib and Golidocitinib Combo Gets NMPA Approval for Phase II Study
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced receiving approval from the National Medical...
Jiangxi Jemincare Gains FDA Approval for Clinical Trial of JYB1907 in Solid Tumors
China – based Jiangxi Jemincare Group has announced that it has received approval from the...
InnoCare Pharma Receives Hong Kong Approval for Tafasitamab in DLBCL
China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the...
Adagene Initiates International Study for ADG126 in Hepatocellular Carcinoma
China-based biotech Adagene Inc. (NASDAQ: ADAG), which also operates out of San Diego, California, has...
GenFleet and Merck KGaA Partner on European Clinical Study for KRAS G12C Inhibitor
China-based GenFleet Therapeutics Inc. has announced a European multi-center clinical study and drug supply agreement...
Henlius Biotech Initiates Phase I Trial for HLX60 in Australia
Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the first subject dosed in a Phase...
Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202
China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical...
Harbour BioMed Concludes Phase I Study for HBM4003 in Advanced Melanoma
Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands,...
Fudan Team Presents Ribociclib Phase II Bridging Study Results at ESMO Asia
A Fudan University Shanghai Cancer Center team led by Shao Zhimin made an oral presentation...
Daiichi Sankyo Doses First Patient in Global Phase III TROPION-Lung08 Study
Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced the first patient dosed in the global multi-center...
Lyvgen Biopharma Initiates Phase II Study for LVGN7409 in Advanced NSCLC
Shanghai-based immuno-oncology therapeutics specialist Lyvgen Biopharma has announced the initiation of an open-label, multi-center, randomized...
Antengene’s ATG-008 Shows Promising Results in Cervical Cancer and Hepatocellular Carcinoma Studies
Shanghai-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced positive preliminary results from the TORCH-2...
Kelun-Biotech’s SKB264 Receives FDA Approval for Phase II Study
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the US FDA to...
Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study
China-based Qilu Pharmaceutical has published the latest results from a Phase II clinical study for...
Akeso Biopharma Completes Enrollment for AK112 Phase III Study
China-based Akeso Biopharma (HKG: 9926) has announced the completion of enrollment for its Phase III...
Hengrui’s Pyrotinib Granted Breakthrough Therapy Designation by CDE
The Center for Drug Evaluation (CDE) website indicates that China-based Hengrui Medicine Co., Ltd’s (SHA:...
Ascletis Signs Pact with Pfizer China for Ritonavir Tablets
Ascletis Pharma Inc. (HKG: 1672) announced that its wholly-owned subsidiary Ascletis Pharmaceuticals Co., Ltd has...
HutchMed Initiates Phase II/III Study for Elunate and Tyvyt in Renal Cell Carcinoma
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase...